Showing 10 posts of 10 posts found.


Novartis’ Xolair scores European approval to treat chronic rhinosinusitis with nasal polyps

August 6, 2020
Sales and Marketing Novartis, Xolair, rhinosinusitis

Novartis has snapped up approval from the European Commission for its anti-immunoglobulin E (IgE) antibody therapy Xolair (omalizumab) for the …


Novartis’ ligelizumab tops Xolair in chronic spontaneous urticaria

January 9, 2020
Research and Development Novartis, Xolair, ligelizumab

Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair …


Novartis’ Xolair shows strong retreatment efficacy at Phase 3 in chronic spontaneous urticaria

September 18, 2017
Research and Development, Sales and Marketing Novartis, Xolair, chronic spontaneous urticarial, pharma, pharmaceutical

Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a …

Roche image

Roche buoyed by cancer drug sales

April 22, 2015
Sales and Marketing Actemra, Cancer, Esbriet, Esbriet., MabThera, Q1, Rituxan, RoActemra, Roche, Xolair, avastin, oncology

Pharma’s biggest cancer drugs maker Roche has reported strong sales growth on the back of its oncology portfolio for its …

NICE approves Roche’s Gazyvaro and Novartis’ Xolair

March 11, 2015
Research and Development, Sales and Marketing Gazyvaro, NICE, Novartis, Roche, Xolair, obinutuzumab, omalizumab

NICE today gave the green light to three new biological drugs, after recommending Roche’s Gazyvaro, GSK’s Arzerra and Novartis’ Xolair …

NICE wants more Xolair data

November 19, 2014
Sales and Marketing Genentech, NHS, NICE, Novartis, UK, Xolair, hives, omalizumab

 Novartis has been asked in draft guidance to give NICE more information before the watchdog can recommend its veteran asthma …

Xolair gets FDA approval for skin condition

March 24, 2014
Research and Development, Sales and Marketing FDA, Novartis, Roche, Sanofi, Xolair, chronic hives, csu

 An asthma drug developed by Roche subsidiary Genentech and Novartis has been granted an additional indication to treat chronic hives …

NICE decides Xolair is not value for money

August 12, 2010
Sales and Marketing NICE, Novartis, Xolair

NICE has refused to back the use of Novartis’ Xolair for young children, saying the asthma drug’s cost brings little …

NICE rejects Xolair for children

June 3, 2010
Sales and Marketing NICE, Xolair, asthma

The drug was first approved in Europe in November 2005 for patients aged 12 or older, and gained NICE approval …

NICE says yes to asthma treatment Xolair

September 6, 2007
Sales and Marketing Xolair

Xolair, a drug which helps control the most severe cases of allergic asthma, has been approved for use on the …

Latest content